BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 390986)

  • 1. A molecular basis of activation of the alternative pathway of human complement.
    Austen KF; Fearon DT
    Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
    Fearon DT; Austen KF
    J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
    Fearon DT; Austen KF
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1683-7. PubMed ID: 266208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
    Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
    J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
    Fearon DT
    Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of the amplification convertase of complement by the plasma protein beta1H.
    Weiler JM; Daha MR; Austen KF; Fearon DT
    Proc Natl Acad Sci U S A; 1976 Sep; 73(9):3268-72. PubMed ID: 1067618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited tryptic cleavage of complement factor H abrogates recognition of sialic acid-containing surfaces by the alternative pathway of complement.
    Koistinen V
    Biochem J; 1992 Apr; 283 ( Pt 2)(Pt 2):317-9. PubMed ID: 1533511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells.
    Lambré CR; Kazatchkine MD; Maillet F; Thibon M
    J Immunol; 1982 Feb; 128(2):629-34. PubMed ID: 6459381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of C3 cleavage in the alternative complement pathway.
    Fearon DT; Austen KF
    J Immunol; 1975 Nov; 115(5):1357-61. PubMed ID: 809512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phagocytosis by human monocytes of particles activating the alternative pathway of complement.
    Johnson E; Eskeland T; Bertheussen K
    Scand J Immunol; 1984 Jan; 19(1):31-9. PubMed ID: 6701471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of granulocyte histaminase release by particle-bound complement C3 cleavage products (C3b, C3bi) and IgG.
    Melamed J; Medicus RG; Arnaout MA; Colten HR
    J Immunol; 1983 Jul; 131(1):439-44. PubMed ID: 6223078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Action of the C3b-inactivator on the cell-bound C3b.
    Law SK; Fearon DT; Levine RP
    J Immunol; 1979 Mar; 122(3):759-65. PubMed ID: 448074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
    Gigli I; Fujita T; Nussenzweig V
    Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.